Patents by Inventor Dulce G. Bubacz

Dulce G. Bubacz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Opioid compounds
    Patent number: 5681830
    Abstract: Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.
    Type: Grant
    Filed: August 3, 1994
    Date of Patent: October 28, 1997
    Assignee: Delta Pharmaceuticals, Inc.
    Inventors: Kwen-Jen Chang, Dulce G. Bubacz, Ann O. Davis, Robert W. McNutt, Jr., Mark A. Collins, Michael J. Bishop
  • Opioid compounds and methods for making therefor
    Patent number: 5574159
    Abstract: Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 12, 1996
    Assignee: Delta Pharmaceuticals, Inc.
    Inventors: Kwen-Jen Chang, Dulce G. Bubacz, Ann O. Davis, Robert W. McNutt, Jr., Michael J. Bishop
  • Opioid compounds and methods for using same
    Patent number: 5552404
    Abstract: Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: September 3, 1996
    Assignee: Delta Pharmaceuticals, Inc.
    Inventors: Kwen-Jen Chang, Dulce G. Bubacz, Ann O. Davis, Robert W. McNutt, Jr., Michael J. Bishop